LINC00460 accelerates progression of ovarian cancer by activating transcriptional factor ZNF703

Wang,Xin; Gan,Xinghua; Liu,Chengcheng; Zhang,Wenfeng

doi:10.3892/ol.2020.11487

LINC00460 accelerates progression of ovarian cancer by activating transcriptional factor ZNF703

Authors:
- Xin Wang
- Xinghua Gan
- Chengcheng Liu
- Wenfeng Zhang
View Affiliations

Affiliations: Department of Gynaecology and Obstetrics, Yuncheng County Hospital of Traditional Chinese Medicine, Heze, Shandong 274700, P.R. China, Department of Gynaecology and Obstetrics, Yan Kuang Xin Li Cheng General Hospital, Jining, Shandong 272000, P.R. China
Published online on: March 27, 2020 https://doi.org/10.3892/ol.2020.11487
Pages: 4189-4194
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Potential function of LINC00460 in the progression of ovarian cancer (OC) and its underlying mechanism were studied. LINC00460 level in OC tissues and normal ovarian tissues was detected by quantitative real‑time polymerase chain reaction (qRT‑PCR). Correlation between LINC00460 level with tumor stage, tumor size and pathological subtypes of OC was analyzed. Potential influence of LINC00460 on proliferative ability and cell cycle progression was evaluated. In vivo tumorigenesis model was conducted by administration of A2780 cells transfected with sh‑NC or sh‑LINC00460 in nude mice. Predicted through JASPAR database, ZNF703 was screened out as the transcriptional factor binding to LINC00460 promoter region. Chromatin immunoprecipitation (ChIP) assay was performed to verify the binding relationship between ZNF703 and LINC00460. The potential role of ZNF703 in LINC00460‑mediated OC progression was examined. LINC00460 was upregulated in OC tissues and cell lines. Its level increased with the deterioration of tumor stage and enlargement of tumor size. LINC00460 was highly expressed in serous ovarian cancer relative to other subtypes of OC. Knockdown of LINC00460 attenuated proliferative ability and arrested cell cycle of A2780 and HO8910 cells. ZNF703 was upregulated in OC tissues. ChIP assay showed pronounced enrichment of LINC00460 in ZNF703. Rescue experiments revealed that ZNF703 overexpression reversed the regulatory effects of LINC00460 on cellular behavior of OC cells. LINC00460 is upregulated in OC tissues and cell lines, which is closely related to tumor progression. It accelerates proliferative ability and cell cycle progression of OC cells via interacting with ZNF703.

View Figures

View References

1	Eisenhauer EA: Real-world evidence in the treatment of ovarian cancer. Ann Oncol. 28 (Suppl 8):viii61–viii65. 2017. View Article : Google Scholar
2	Webb PM and Jordan SJ: Epidemiology of epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 41:3–14. 2017. View Article : Google Scholar : PubMed/NCBI
3	Nammalwar B, Bunce RA, Berlin KD, Benbrook DM and Toal C: Synthesis and biological evaluation of SHetA2 (NSC-721689) analogs against the ovarian cancer cell line A2780. Eur J Med Chem. 170:16–27. 2019. View Article : Google Scholar : PubMed/NCBI
4	Marchetti C, De Felice F, Perniola G, Palaia I, Musella A, Di Donato V, Cascialli G, Muzii L, Tombolini V and Benedetti Panici P: Role of intraperitoneal chemotherapy in ovarian cancer in the platinum-taxane-based era: A meta-analysis. Crit Rev Oncol Hematol. 136:64–69. 2019. View Article : Google Scholar : PubMed/NCBI
5	Andersen RE and Lim DA: Forging our understanding of lncRNAs in the brain. Cell Tissue Res. 371:55–71. 2018. View Article : Google Scholar : PubMed/NCBI
6	Huarte M: The emerging role of lncRNAs in cancer. Nat Med. 21:1253–1261. 2015. View Article : Google Scholar : PubMed/NCBI
7	Peng WX, Koirala P and Mo YY: LncRNA-mediated regulation of cell signaling in cancer. Oncogene. 36:5661–5667. 2017. View Article : Google Scholar : PubMed/NCBI
8	Liu X, Wen J, Wang H and Wang Y: Long non-coding RNA LINC00460 promotes epithelial ovarian cancer progression by regulating microRNA-338-3p. Biomed Pharmacother. 108:1022–1028. 2018. View Article : Google Scholar : PubMed/NCBI
9	Ye JJ, Cheng YL, Deng JJ, Tao WP and Wu L: LncRNA LINC00460 promotes tumor growth of human lung adenocarcinoma by targeting miR-302c-5p/FOXA1 axis. Gene. 685:76–84. 2019. View Article : Google Scholar : PubMed/NCBI
10	Zhang Y, Liu X, Li Q and Zhang Y: lncRNA LINC00460 promoted colorectal cancer cells metastasis via miR-939-5p sponging. Cancer Manag Res. 11:1779–1789. 2019. View Article : Google Scholar : PubMed/NCBI
11	Ma G, Zhu J, Liu F and Yang Y: Long Noncoding RNA LINC00460 promotes the gefitinib resistance of nonsmall cell lung cancer through epidermal growth factor receptor by sponging miR-769-5p. DNA Cell Biol. 38:176–183. 2019. View Article : Google Scholar : PubMed/NCBI
12	Wang F, Liang S, Liu X, Han L, Wang J and Du Q: LINC00460 modulates KDM2A to promote cell proliferation and migration by targeting miR-342-3p in gastric cancer. OncoTargets Ther. 11:6383–6394. 2018. View Article : Google Scholar
13	Ge SS, Wu YY, Gao W, Zhang CM, Hou J, Wen SX and Wang BQ: Expression of long non-coding RNA LINC00460 in laryngeal squamous cell carcinoma tissue and its clinical significance. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 32:18–22. 2018.(In Chinese). PubMed/NCBI
14	Kong YG, Cui M, Chen SM, Xu Y, Xu Y and Tao ZZ: LncRNA-LINC00460 facilitates nasopharyngeal carcinoma tumorigenesis through sponging miR-149-5p to up-regulate IL6. Gene. 639:77–84. 2018. View Article : Google Scholar : PubMed/NCBI
15	Liang Y, Wu Y, Chen X, Zhang S, Wang K, Guan X, Yang K, Li J and Bai Y: A novel long noncoding RNA linc00460 up-regulated by CBP/P300 promotes carcinogenesis in esophageal squamous cell carcinoma. Biosci Rep. 37:372017. View Article : Google Scholar
16	Zhao G, Fu Y, Su Z and Wu R: How long non-coding RNAs and MicroRNAs mediate the endogenous RNA Network of head and neck squamous cell carcinoma: A comprehensive analysis. Cell Physiol Biochem. 50:332–341. 2018. View Article : Google Scholar : PubMed/NCBI
17	Vlad C, Dina C, Kubelac P, Vlad D, Pop B and Achimas Cadariu P: Expression of toll-like receptors in ovarian cancer. J BUON. 23:1725–1731. 2018.PubMed/NCBI
18	Zhou H, Zhao H, Liu H, Xu X, Dong X and Zhao E: Influence of carboplatin on the proliferation and apoptosis of ovarian cancer cells through mTOR/p70s6k signaling pathway. J BUON. 23:1732–1738. 2018.PubMed/NCBI
19	Yang X, Guo F, Peng Q, Liu Y and Yang B: Suppression of in vitro and in vivo human ovarian cancer growth by isoacteoside is mediated via sub-G1 cell cycle arrest, ROS generation, and modulation of AKT/PI3K/m-TOR signalling pathway. J BUON. 24:285–290. 2019.PubMed/NCBI
20	Ottevanger PB: Ovarian cancer stem cells more questions than answers. Semin Cancer Biol. 44:67–71. 2017. View Article : Google Scholar : PubMed/NCBI
21	Ding SS, Li L and Yu CX: Systematic evaluation of bevacizumab in recurrent ovarian cancer treatment. J BUON. 19:965–972. 2014.PubMed/NCBI
22	Maduro MR: Potential biomarkers for ovarian cancer. Reprod Sci. 26:4492019. View Article : Google Scholar : PubMed/NCBI
23	Worku T, Bhattarai D, Ayers D, Wang K, Wang C, Rehman ZU, Talpur HS and Yang L: Long non-coding RNAs: The new horizon of gene regulation in ovarian cancer. Cell Physiol Biochem. 44:948–966. 2017. View Article : Google Scholar : PubMed/NCBI
24	Fu LL, Li CJ, Xu Y, Li LY, Zhou X, Li DD, Chen SX, Wang FG, Zhang XY and Zheng LW: Role of lncRNAs as novel biomarkers and therapeutic targets in ovarian cancer. Crit Rev Eukaryot Gene Expr. 27:183–195. 2017. View Article : Google Scholar : PubMed/NCBI
25	An J, Lv W and Zhang Y: LncRNA NEAT1 contributes to paclitaxel resistance of ovarian cancer cells by regulating ZEB1 expression via miR-194. OncoTargets Ther. 10:5377–5390. 2017. View Article : Google Scholar
26	Li AH and Zhang HH: Overexpression of lncRNA MNX1-AS1 is associated with poor clinical outcome in epithelial ovarian cancer. Eur Rev Med Pharmacol Sci. 21:5618–5623. 2017.PubMed/NCBI
27	Dou Q, Xu Y, Zhu Y, Hu Y, Yan Y and Yan H: LncRNA FAM83H-AS1 contributes to the radioresistance, proliferation, and metastasis in ovarian cancer through stabilizing HuR protein. Eur J Pharmacol. 852:134–141. 2019. View Article : Google Scholar : PubMed/NCBI
28	Zhang Y, Dun Y, Zhou S and Huang XH: LncRNA HOXD-AS1 promotes epithelial ovarian cancer cells proliferation and invasion by targeting miR-133a-3p and activating Wnt/β-catenin signaling pathway. Biomed Pharmacother. 96:1216–1221. 2017. View Article : Google Scholar : PubMed/NCBI
29	Yuan J, Liu Z and Song R: Antisense lncRNA As-SLC7A11 suppresses epithelial ovarian cancer progression mainly by targeting SLC7A11. Pharmazie. 72:402–407. 2017.PubMed/NCBI
30	Dong S, Wang R, Wang H, Ding Q, Zhou X, Wang J, Zhang K, Long Y, Lu S, Hong T, et al: HOXD-AS1 promotes the epithelial to mesenchymal transition of ovarian cancer cells by regulating miR-186-5p and PIK3R3. J Exp Clin Cancer Res. 38:1102019. View Article : Google Scholar : PubMed/NCBI
31	Li K, Sun D, Gou Q, Ke X, Gong Y, Zuo Y, Zhou JK, Guo C, Xia Z, Liu L, et al: Long non-coding RNA linc00460 promotes epithelial-mesenchymal transition and cell migration in lung cancer cells. Cancer Lett. 420:80–90. 2018. View Article : Google Scholar : PubMed/NCBI
32	Yue QY and Zhang Y: Effects of Linc00460 on cell migration and invasion through regulating epithelial-mesenchymal transition (EMT) in non-small cell lung cancer. Eur Rev Med Pharmacol Sci. 22:1003–1010. 2018.PubMed/NCBI